

Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

Information for the public

Published: 24 June 2026

www.nice.org.uk

Mirvetuximab soravtansine (Elahere) is available on the NHS. It is a possible treatment for folate receptor-alpha positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after 1 to 3 lines of systemic treatment.

Platinum resistant means that the cancer initially responded to platinum-based chemotherapy (such as cisplatin or carboplatin in combination with paclitaxel), but then came back or started growing again within 6 months after stopping platinum-based chemotherapy.

Lines of treatment are a sequence of treatments, starting with the most suitable option and moving to alternatives if the first does not work or the condition gets worse. Each line can be a single drug or a combination of drugs. A systemic treatment is a treatment that works throughout the whole body.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on ovarian cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Ovarian Cancer Action](#), 020 7380 1730
- [Ovacome](#), 0800 008 7054
- [Target Ovarian Cancer](#), 0808 802 6000
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-9555-4